Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury: A review

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 5, 2010, Pages 519-531

  Njoku, Dolores B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2E1; DILI; Drug haptens; Halogenated anesthetics; IL 4; Trifluoroacetyl chloride

Indexed keywords

CARBON TETRACHLORIDE; CD4 ANTIGEN; COLLAGEN; CONCANAVALIN A; HAPTEN; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; LIPOPOLYSACCHARIDE; PARACETAMOL;

ANTIGEN RECOGNITION; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL POPULATION; CHRONIC HEPATITIS; ENCEPHALITIS; EXPERIMENTAL MODEL; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LIVER INJURY; LIVER TOXICITY; MYOCARDITIS; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; TOXIC HEPATITIS;

ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; CYTOCHROME P-450 CYP2E1; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; HAPTENS; HUMANS; INFLAMMATION; INTERLEUKIN-4; PHARMACEUTICAL PREPARATIONS;

ANIMALIA;

EID: 77951276363     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425251003601979     Document Type: Review

References (67)

1. Schiodt FV, Atillasoy E, Shakil AO, et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg 1999;5:29-34 (Pubitemid 29037351)
2. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-954 (Pubitemid 35440240)
3. Castell JV. Allergic hepatitis: a drugmediated organ-specific immune reaction. Clin Exp Allergy 1998;28(Suppl 4):13-19 (Pubitemid 28429660)
4. Adkinson NF Jr, Essayan D, Gruchalla R, et al. Task force report: future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions. J Allergy Clin Immunol 2002;109:S461-78 (Pubitemid 34234216)
5. Mackay IR, Toh BH. Autoimmune hepatitis: the way we were, the way we are today and the way we hope to be. Autoimmunity 2002;35:293-305
6. Neuberger J, Mieli-Vergani G, Tredger JM, et al. Oxidative metabolism of halothane in the production of altered hepatocyte membrane antigens in acute halothane-induced hepatic necrosis. Gut 1981;22:669-672 (Pubitemid 11018272)
7. Pohl LR, Thomassen D, Pumford NR, et al. Hapten carrier conjugates associated with halothane hepatitis. Adv Exp Med Biol 1991;283:111-120
8. Njoku D, Laster MJ, Gong DH, et al. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth Analg 1997;84:173-178 (Pubitemid 27020979)
9. Njoku DB, Talor MV, Fairweather D, et al. A novel model of drug hapten-induced hepatitis with increased mast cells in the BALB/c mouse. Exp Mol Pathol 2005;78:87-100 (Pubitemid 40248789)
10. Njoku DB, Li Z, Washington ND, et al. Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury. Eur J Immunol 2009;39:1652-1663
11. Martin JL, Kenna JG, Martin BM, et al. Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase. Hepatology 1993;18:858-863
12. Eliasson E, Kenna JG. Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. Mol Pharmacol 1996;50:573-582 (Pubitemid 26303588)
13. Bourdi M, Chen W, Peter RM, et al. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 1996;9:1159-1166 (Pubitemid 26347970)
14. Njoku DB, Greenberg RS, Bourdi M, et al. Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists. Anesth Analg 2002;94:243-249,table of contents (Pubitemid 34106808)
15. Njoku DB, Mellerson JL, Talor MV, et al. Role of CYP2E1 immunoglobulin G4 subclass antibodies and complement in pathogenesis of idiosyncratic drug-induced hepatitis. Clin Vaccine Immunol 2006;13:258-265
16. Aithal GP, Ramsay L, Daly AK, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004;39:1430-1440 (Pubitemid 38569066)
17. Gascan H, Gauchat JF, Roncarolo MG, et al. Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones. J Exp Med 1991;173:747-750
18. Zhang K, Clark EA, Saxon A. CD40 stimulation provides an IFN-gamma-independent and IL-4-dependent differentiation signal directly to human B cells for IgE production. J Immunol 1991;146:1836-1842
19. Svensson L, Nandakumar KS, Johansson A, et al. IL-4-deficient mice develop less acute but more chronic relapsing collagen-induced arthritis. Eur J Immunol 2002;32:2944-2953 (Pubitemid 35243645)
20. Gascan H, Gauchat JF, Aversa G, et al. Anti-CD40 monoclonal antibodies or CD4+ T cell clones and IL-4 induce IgG4 and IgE switching in purified human B cells via different signaling pathways. J Immunol 1991;147:8-13
21. Anderson JS, Rose NR, Martin JL, et al. Desflurane hepatitis associated with hapten and autoantigen-specific IgG4 antibodies. Anesth Analg 2007;104:1452-1453,table of contents
22. Nguyen C, Rose NR, Njoku DB. Trifluoroacetylated IgG4 antibodies in a child with idiosyncratic acute liver failure after first exposure to halothane. J Pediatr Gastroenterol Nutr 2008;47:199-202
23. Tato CM, Laurence A, O'Shea JJ. Helper T cell differentiation enters a new era: le roi est mort; vive le roi! J Exp Med 2006;203:809-812
24. Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993;44:707-715 (Pubitemid 23317282)
25. Pricop L, Redecha P, Teillaud JL, et al. Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J Immunol 2001;166:531-537 (Pubitemid 32038473)
26. Moretta L, Ferlazzo G, Bottino C, et al. Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev 2006;214:219-228 (Pubitemid 44707913)
27. Balato A, Unutmaz D, Gaspari AA. Natural killer T cells: an unconventional T-cell subset with diverse effector and regulatory functions. J Invest Dermatol 2009;129:1628-1642
28. Nelms K, Keegan AD, Zamorano J, et al. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999;17:701-738 (Pubitemid 29241138)
29. Huppa JB, Davis MM. T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol 2003;3:973-983
30. Zhou H, Su HS, Zhang X, et al. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant. J Immunol 1997;158:4741-4749 (Pubitemid 127483794)
31. Douhan J, Lieberson R, Knoll JH, et al. An isotype-specific activator of major histocompatibility complex (MHC) class II genes that is independent of class II transactivator. J Exp Med 1997;185:1885-1895 (Pubitemid 27247075)
32. Outschoorn I, Rowley MJ, Cook AD, Mackay IR. Subclasses of immunoglobulins and autoantibodies in autoimmune diseases. Clin Immunol Immunopathol 1993;66:59-66 (Pubitemid 23069256)
33. Caturegli P, Kuppers RC, Mariotti S, et al. IgG subclass distribution of thyroglobulin antibodies in patients with thyroid disease. Clin Exp Immunol 1994;98:464-469 (Pubitemid 24374733)
34. Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009;39:469-477
35. Makino S, Kunimoto K, Muraoka Y, et al. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 1980;29:1-13 (Pubitemid 10185796)
36. Turley S, Poirot L, Hattori M, et al. Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med 2003;198:1527-1537 (Pubitemid 37467167)
37. Yu L, Robles DT, Abiru N, et al. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci USA 2000;97:1701-1706 (Pubitemid 30118506)
38. McDevitt HO, Unanue ER. Autoimmune diabetes mellitus-much progress, but many challenges. Adv Immunol 2008;100:1-12
39. Yamamoto AM, Chernajovsky Y, Lepault F, et al. The activity of immunoregulatory T cells mediating active tolerance is potentiated in nonobese diabetic mice by an IL-4-based retroviral gene therapy. J Immunol 2001;166:4973-4980 (Pubitemid 32280708)
40. Brusko TM, Putnam AL, Bluestone JA. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 2008;223:371-390 (Pubitemid 351986182)
41. Skapenko A, Kalden JR, Lipsky PE, Schulze-Koops H. The IL-4 receptor alpha-chain-binding cytokines, IL-4 and IL-13, induce forkhead box P3-expressing CD25+CD4+ regulatory T cells from CD25-CD4+ precursors. J Immunol 2005;175:6107-6116
42. You S, Alyanakian MA, Segovia B, et al. Immunoregulatory pathways controlling progression of autoimmunity in NOD mice. Ann NY Acad Sci 2008;1150:300-310
43. Xu L, Huang Y, Yang J, et al. Dendritic cell-derived nitric oxide is involved in IL-4-induced suppression of experimental allergic encephalomyelitis (EAE) in Lewis rats. Clin Exp Immunol 1999;118:115-121 (Pubitemid 29479792)
44. Horsfall AC, Butler DM, Marinova L, et al. Suppression of collageninduced arthritis by continuous administration of IL-4. J Immunol 1997;159:5687-5696 (Pubitemid 127470100)
45. Cihakova D, Barin JG, Afanasyeva M, et al. Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am J Pathol 2008;172:1195-1208 (Pubitemid 351671534)
46. Harrill AH, Ross PK, Gatti DM, et al. Population-based discovery of toxicogenomics biomarkers for hepatotoxicity using a laboratory strain diversity panel. Toxicol Sci 2009;110:235-243
47. Jaruga B, Hong F, Sun R, et al. Crucial role of IL-4/STAT6 in T cell-mediated hepatitis: up-regulating eotaxins and IL-5 and recruiting leukocytes. J Immunol 2003;171:3233-3244 (Pubitemid 37093550)
48. Moscat J, Rennert P, Diaz-Meco MT. PKCzeta at the crossroad of NF-kappaB and Jak1/Stat6 signaling pathways. Cell Death Differ 2006;13:702-711
49. Sass G, Heinlein S, Agli A, et al. Cytokine expression in three mouse models of experimental hepatitis. Cytokine 2002;19:115-120 (Pubitemid 35216191)
50. Tsutsui H, Adachi K, Seki E, Nakanishi K. Cytokine-induced inflammatory liver injuries. Curr Mol Med 2003;3:545-559 (Pubitemid 37168597)
51. Shi Z, Wakil AE, Rockey DC. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci USA 1997;94:10663-10668 (Pubitemid 27430791)
52. Bourdi M, Eiras DP, Holt MP, et al. Role of IL-6 in an IL-10 and IL-4 double knockout mouse model uniquely susceptible to acetaminophen-induced liver injury. Chem Res Toxicol 2007;20:208-216 (Pubitemid 46408857)
53. Pohl LR, Kenna JG, Satoh H, et al. Neoantigens associated with halothane hepatitis. Drug Metab Rev 1989;20:203-217 (Pubitemid 19277697)
54. Anderson CF, Oukka M, Kuchroo VJ, Sacks D. CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 2007;19(204):285-297 (Pubitemid 46294545)
55. Ji H, Pettit A, Ohmura K, et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med 2002;196:77-85 (Pubitemid 34747313)
56. Selzner N, Selzner M, Tian Y, et al. Cold ischemia decreases liver regeneration after partial liver transplantation in the rat: a TNF-alpha/ IL-6-dependent mechanism. Hepatology 2002;36:812-818
57. Williams BD, White N, Amlot PL, et al. Circulating immune complexes after repeated halothane anaesthesia. Br Med J 1977;2:159-162 (Pubitemid 8138854)
58. Itoh N, Hanafusa T, Katsura H, et al. Two types of autoantibodies to adrenal medullary cells in Type 1 (insulin-dependent) diabetic patients: prevalence, properties and implications. J Autoimmun 1991;4:807-818
59. Horneff G, Lenard HG, Wahn V. Severe adverse reaction to carbamazepine: significance of humoral and cellular reactions to the drug. Neuropediatrics 1992;23:272-275
60. van der Zee JS, van Swieten P, Aalberse RC. Inhibition of complement activation by IgG4 antibodies. Clin Exp Immunol 1986;64:415-422 (Pubitemid 16102170)
61. Oliveira DB. Membranous nephropathy: an IgG4-mediated disease. Lancet 1998;351:670-671
62. Porubsky PR, Meneely KM, Scott EE. Structures of human cytochrome P-450 2E1. Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates. J Biol Chem 2008;283:33698-33707
63. Vidali M, Occhino G, Ivaldi A, et al. Detection of auto-antibodies against cytochrome P4502E1 (CYP2E1) in chronic hepatitis C. J Hepatol 2007;46:605-612 (Pubitemid 46400145)
64. Nakai K, Tanaka H, Hanada K, et al. Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholatecotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients. Drug Metab Dispos 2008;36:1786-1793
65. Rigamonti C, Vidali M, Donato MF, et al. Serum autoantibodies against cytochrome P450 2E1 (CYP2E1) predict severity of necroinflammation of recurrent hepatitis C. Am J Transplant 2009;9:601-609
66. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008;48:353-367
67. Iannello A, Samarani S, Debbeche O, et al. Role of interleukin-18 in the development and pathogenesis of AIDS. AIDS Rev 2009;11:115-125